Aragon Pharmaceuticals, Inc v. Lupin Limited

Court

District Court, D. New Jersey (D.N.J.)
Official Court Website →

Assigned judge

Stanley R. Chesler · 3,374 cases in index

Docket number

2:22-cv-02825

Cause

15:1126 Patent Infringement
15 U.S.C. § 1126

Nature of suit

835 Patent - Abbreviated New Drug Application(ANDA)
Hatch-Waxman patent disputes over a generic-drug (ANDA) application.

Jurisdiction

Federal Question

Jury demand

None

Date filed

05/13/2022

Date terminated

12/11/2023

623 Patent - ANDA cases in this court are indexed here.

Parties

• plaintiff · Aragon Pharmaceuticals, Inc · 6 cases
• defendant · Lupin Limited · 108 cases

About Patent - ANDA Lawsuits

ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

Frequently Asked Questions

What is Aragon Pharmaceuticals, Inc v. Lupin Limited?

Aragon Pharmaceuticals, Inc v. Lupin Limited is a federal patent - anda lawsuit filed on 05/13/2022 in the District Court, D. New Jersey. The case was terminated on 12/11/2023. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What type of case is this?

It is classified as “Patent - ANDA” under the federal nature-of-suit system. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What court is the case in?

The case is in the District Court, D. New Jersey, docket number 2:22-cv-02825.

When was the case filed?

Aragon Pharmaceuticals, Inc v. Lupin Limited was filed on 05/13/2022. It was terminated on 12/11/2023.

What law is the case brought under?

The docket lists the cause as 15 U.S.C. § 1126.